



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Kaufman, J;Attwell, K;Hauck, Y;Leask, J;Omer, SB;Regan, A;Danchin, M

Title:

Designing a multi-component intervention (P3-MumBubVax) to promote vaccination in antenatal care in Australia

Date:

2021-07-01

Citation:

Kaufman, J., Attwell, K., Hauck, Y., Leask, J., Omer, S. B., Regan, A. & Danchin, M. (2021). Designing a multi-component intervention (P3-MumBubVax) to promote vaccination in antenatal care in Australia. *Health Promotion Journal of Australia*, 32 (3), pp.391-398. <https://doi.org/10.1002/hpja.382>.

Persistent Link:

<https://hdl.handle.net/11343/276053>

Designing a multi-component intervention (P3-MumBubVax) to promote vaccination in antenatal care in Australia

Running title: Antenatal vaccine promotion intervention

Jessica Kaufman, PhD^{*a,b}, Katie Attwell, PhD^{c,d}, Yvonne Hauck, BScN, MSc, PhD^{e,f}, Julie Leask, PhD, MPH, Midwifery Cert., Dip Health Sci^g, Saad B. Omer, MBBS MPH PhD FIDSA^h, Annette Regan, PhD, MPHⁱ, Margie Danchin, MBBS PhD FRACP^{a,b,d}

^a Murdoch Children's Research Institute, Australia

^b Department of Paediatrics, University of Melbourne, Australia

^c School of Social Sciences, University of Western Australia, Australia

^d Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Australia

^e School of Nursing, Midwifery & Paramedicine, Curtin University, Australia

^f Department of Nursing and Midwifery Education and Research, King Edward Memorial Hospital, Australia

^g Faculty of Medicine and Health, University of Sydney, Australia

^h Rollins School of Public Health, Emory University, USA

ⁱ School of Public Health, Texas A&M University, USA

** Corresponding author*

Acknowledgements

We thank the participating midwives from both hospitals, and clinic managers Barb Lourey and Trish Ryan for their coordination efforts and their investment of staff time in this research. We acknowledge and thank our wider team who consulted on study design: Helen Marshall, Kerrie Wiley, Tom Snelling and Penny Haora. We also thank our research assistants Annette Alafaci and Shevaun Drislane, and undergraduate student Phoebe Levin (who ably assisted in the KEMH focus

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/HPJA.382](https://doi.org/10.1002/HPJA.382)

This article is protected by copyright. All rights reserved

group). We particularly acknowledge the long-term interest and investment in this project by Paul Effler of the Communicable Disease Control Directorate, on behalf of the Government of Western Australia, Department of Health.

Conflict of interest

Katie Attwell has previously been employed by the Immunisation Alliance of Western Australia to conduct social research using an unrestricted grant from Sanofi Pasteur. She has received travel, accommodation and conference registration support from GSK, and travel, accommodation and speaker fees from Merck. The other authors report no conflicts.

Funding

This work was supported by the Communicable Disease Control Directorate, Department of Health, Government of Western Australia [grant number DOH2017 1330]. The study funder had no role in study design, data collection or analysis, or writing of the manuscript. MD is funded by the University of Melbourne Bickart Clinician Research Fellowship.

Author contributions

MD, KA, JK and SBO drafted the methodology for the study. The interviews and focus groups were conducted by JK, KA and YH. JK and KA analysed the data, with input from YH and MD. All authors provided input and/or feedback on intervention elements, with JL and AR providing particular input on SKAI-related elements and text messages, respectively. SBO provided substantial input and guidance in the application of the P3 model and adaptation of VaxChat. All authors contributed to drafts of the manuscript and approved the final submitted version.

1

2 DR JESSICA KAUFMAN (Orcid ID : 0000-0001-5139-4183)

3

4

5 Article type : Brief Report

6

7

Designing a multi-component intervention (P3-MumBubVax) to promote vaccination in antenatal care in Australia

Keywords

midwifery; vaccination; health promotion; health services; communication; maternal health services; implementation science

8 Abstract

9 Issue addressed

10 Coverage of maternal influenza and pertussis vaccines remains suboptimal in Australia, and pockets
11 of low childhood vaccine coverage persist nationwide. Maternal vaccine uptake is estimated to be
12 between 35% and 60% for influenza vaccination and between 65% and 80% for pertussis
13 vaccination. Australian midwives are highly trusted and ideally-placed to discuss vaccines with
14 expectant parents, but there are no evidence-based interventions to optimise these discussions and
15 promote maternal and childhood vaccine acceptance in the Australian public antenatal setting.

16 Methods

17 We gathered qualitative data from Australian midwives, reviewed theoretical models, and adapted
18 existing vaccine communication tools to develop the multi-component P3-MumBubVax intervention.
19 Through 12 interviews at two Australian hospitals, we explored midwives' vaccination attitudes and

20 values, perceived role in vaccine advocacy and delivery, and barriers and enablers to intervention
21 implementation. Applying the theory-based P3 intervention model, we designed intervention
22 components targeting the Practice, Provider and Parent levels. Midwives provided feedback on
23 prototype intervention features through two focus groups.

24 Results

25 The P3-MumBubVax intervention includes practice-level prompts and identification of a vaccine
26 champion. Provider-level components are a vaccine communication training module, learning
27 exercise, and website with printable fact sheets. Parent-level intervention components include text
28 message reminders to receive influenza and pertussis vaccines in pregnancy, as well as online
29 information on vaccine safety, effectiveness and disease severity.

30 Conclusions

31 The P3-MumBubVax intervention is the first Australian antenatal intervention designed to support
32 both maternal and childhood vaccine uptake. A pilot study is underway to inform a planned cluster
33 randomised controlled trial.

34 So what?

35 Barriers to vaccine acceptance and uptake are complex. The P3 model is a promising evidence-
36 informed multi-component intervention strategy targeting all three levels influencing healthcare
37 decision-making.

38

39 Background

40 Vaccination for influenza and pertussis during pregnancy protects both pregnant women and infants,
41 but maternal vaccination coverage in Australia remains sub-optimal. Maternal influenza vaccination
42 coverage is estimated to be between 35-60%, and pertussis coverage between 65-80% (1, 2).

43 Pockets of low childhood vaccine coverage also persist. This leaves many pregnant women and their
44 infants vulnerable to the morbidity and mortality associated with these vaccine-preventable
45 diseases.

46 Reviews find that the most effective strategies involve multi-component interventions (3, 4).

47 Interventions targeting practices, providers and patients have shown promise for promoting
48 maternal, adolescent or childhood vaccines in other countries. They involve provider and patient
49 reminders, informational resources addressing vaccine effectiveness and safety, and structural
50 levers such as on-site vaccinations and standing orders (no prescription required) (5-10). "P3" is an

51 innovative, theory-based intervention model developed at Emory University, USA to design
52 intervention components at the three interconnected levels of healthcare delivery (5, 6). P3 applies
53 strategies from behavioural economics and builds on the Health Belief Model, Social Cognitive
54 Theory, and the Systems Model of Clinical Preventive Care (5).

55 Provider recommendation is the primary driver of vaccine uptake in antenatal care settings (6, 11),
56 and expectant parents want to discuss maternal and childhood vaccines in pregnancy (12). In
57 Australia, midwives are a key healthcare provider to discuss vaccines and facilitate uptake. They are
58 highly trusted and play a major role in antenatal care (12), particularly in the public hospital setting
59 where three-quarters of Australian women give birth (13). Australian midwives generally support
60 antenatal vaccination and view it as part of their role, but they receive limited education on
61 immunisation or how to discuss vaccines with expectant parents (14-16).

62 A P3 maternal vaccination intervention has been piloted (6) and is currently being evaluated in the
63 US setting with obstetricians, but no such model has been tested in the Australian public antenatal
64 setting. Therefore, building on theory and existing interventions, and in consultation with Australian
65 midwives, we iteratively designed a multi-component P3 intervention to optimise midwives' vaccine
66 discussions with expectant parents and improve uptake of maternal and childhood vaccines.

67 Methods

68 This "P3-MumBubVax" intervention package was developed through two rounds of formative
69 qualitative research (17). The Round 1 exploratory stage, described in full elsewhere (16), included
70 12 in-depth interviews with midwives at a tertiary maternity hospital in Western Australia, where
71 immunisation-accredited midwives deliver maternal vaccines onsite, and another in Victoria, where
72 maternal vaccines are not routinely delivered onsite. The interviews explored midwives' vaccination
73 needs, values, practice and preferences. We then designed a prototype intervention package based
74 on the key findings from Round 1, previous research with parents (11, 12, 18-21), and existing
75 interventions like the US-based P3 intervention and the Australian SKAI (Sharing Knowledge about
76 Immunisation) childhood vaccination package for primary care providers and parents (5, 18).

77 In the Round 2 pretesting stage, we solicited feedback on intervention ideas and prototype designs
78 through midwife focus groups at the same hospitals. Participants discussed their preferred
79 intervention length, terminology, format, design and content; current training; vaccine
80 recommendations; likelihood of utilising intervention components; and goals for antenatal vaccine
81 discussions (Appendix 1).

82 Midwives were recruited for interviews and focus groups with support from clinic managers at each
83 site. Participants agreed consent, completed a demographic survey, and received \$25 for their time.
84 Ethics approval was obtained in Western Australia (RGS0000000736) and Victoria (HREC 37338A).
85 Interviews and focus groups were recorded, transcribed, and analysed in two separate rounds of
86 thematic template analysis (22).

87 Results

88 Participants

89 Twelve midwives participated in interviews: seven in Victoria (VIC) and five in Western Australia
90 (WA) (interview participant demographics published elsewhere) (16). Two focus groups were held,
91 involving five midwives in VIC and thirteen in WA (Table 1). Three midwives from the WA focus
92 group had previously participated in Round 1 interviews.

93 Summary of findings

94 In the Round 1 interviews, midwives were willing to make a recommendation to vaccinate, and
95 wanted training and informational resources about vaccines for themselves and to share with
96 parents in a variety of formats (16).

97 Focus group participants in Round 2 shared similar views and experiences, confirming that our
98 proposed intervention was suitable and aligned with their professional ethos. Common themes
99 included the importance of informed choice; maintaining strong relationships with expectant
100 parents; a need for succinct, easy-to-access vaccine and disease facts and information sources to
101 support their discussions; and a desire for more skills in responding to vaccine misperceptions
102 and/or concerns. The focus groups shaped the format, content and language we used in the final
103 intervention.

104 P3-MumBubVax intervention components

105 The finalised intervention components, informed by our qualitative findings, are outlined in Figure 1
106 and are described below. Given the variation in models of antenatal care across states and hospitals
107 in Australia, aspects of the intervention would need to be modified for the local context (e.g.
108 provision of vaccines onsite, paper vs Electronic Medical Records (EMRs)).

109 Practice-level components

110 **Sticker prompts:** We created physical stickers for paper maternity records or other medical charts to
111 record not only when women received vaccines (either onsite or elsewhere), but also when the

112 midwives discussed vaccines with expectant parents. Where hospitals use EMRs, stickers could be
113 replaced by digital prompts.

114 **Vaccine champion:** We identified a midwife or clinic manager at each site to act as a ‘vaccine
115 champion’, to facilitate intervention implementation and promote vaccination.

116 Provider-level components

117 **Online communication and education training:** To support vaccine recommendations and provide
118 midwives with training on communication strategies and key facts about maternal and childhood
119 vaccines and vaccine-preventable diseases, we produced an online training video called VaxChat
120 Australia. This was adapted from a training video developed for US obstetricians by the Emory
121 University P3 team (5). The communication approach was also informed by the SKAI intervention
122 package, which applies principles of Motivational Interviewing to address childhood vaccines (23).

123 VaxChat Australia is broken into three sections: (i) framing (structure of message delivery), (ii)
124 content (what you recommend), and (iii) your clinic (making vaccination routine). The video also
125 provides guidance about introducing other childhood vaccines and highlights that the website is
126 linked to the comprehensive SKAI resource.

127 **Personalised vaccine discussion cheat sheet:** After watching VaxChat Australia, midwives complete
128 an online ‘cheat sheet’ to select key vaccine facts they want to have on hand for easy recall and
129 point-of-care use. In this exercise, midwives select one key fact from a list of 3-5 facts for each of the
130 following topics: general vaccine safety; influenza, pertussis, and hepatitis B severity; flu, pertussis,
131 and hepatitis B vaccine safety; and flu, pertussis, and hepatitis B vaccine benefits. The final list of 10
132 facts is emailed to them in a format that fits into a lanyard ID badge.

133 **MumBubVax website:** The provider portal of the MumBubVax website is home to the VaxChat
134 Australia training video and learning exercise, data on vaccine safety and effectiveness and disease
135 severity, and brief downloadable fact sheets.

136 Parent-level components

137 **Parent prompts - text message reminders:** We developed text message reminders for clinics to send
138 to pregnant women about maternal influenza and pertussis vaccines. Women at the VIC hospital
139 were directed to GPs to receive the vaccines, but the message could instead state that the vaccines
140 would be provided at an upcoming antenatal appointment.

141 Message timing, frequency and content drew from evidence (10, 20) and our Round 1 midwife
142 interviews. Messages were personalised and the sender was identified as the woman’s antenatal

143 clinic to enhance credibility (20). Messages opened with a statement about disease severity,
144 emphasised vaccine effectiveness, and ended with a call to action.

145 Our midwife participants discussed influenza at the booking visit (16-20 weeks) and pertussis around
146 28 weeks, in keeping with the national recommendations at the time of our data collection.
147 However, timing for pertussis vaccine delivery has been changed to 20 weeks (24). For future
148 implementation of this intervention, the reminders will therefore be sent to women twice following
149 their booking visit, to prompt both influenza and pertussis vaccination, with a follow-up reminder
150 after the 28-week visit.

151 **MumBubVax website:** The parent-facing MumBubVax website features detailed vaccine and disease
152 information. Midwives expressed that online resources for parents were valuable, but most available
153 resources were overly simplistic. Website information is broken into expandable tiered sections so
154 parents seeking extensive vaccine safety and effectiveness information can access it, but it is not
155 overwhelming. It is framed to highlight the risks of influenza and pertussis to the infant, based on
156 research showing that women are more concerned about risks to their babies than risks to their own
157 health (11). The resources emphasise the severity of influenza, which many women see as less
158 serious than pertussis (19). The site also includes downloadable fact sheets and infographics on
159 pertussis, influenza and birth hepatitis B, and links to extensive childhood vaccine information
160 through the SKAI website.

161 Discussion

162 The P3-MumBubVax intervention is designed to address the needs and preferences of Australian
163 midwives and expectant parents. It is innovative and scalable, while also building on evidence and
164 theory from Australia (18), Canada (8) and the US (5-7, 10). It seamlessly links with the SKAI website,
165 which provides high-quality information about childhood vaccines, reflecting expectant parents'
166 preferences for this information in pregnancy (12). A review of interventions to increase maternal
167 vaccine uptake, published after the design of our intervention, supports many of the concepts and
168 features of P3-MumBubVax (3).

169 The intervention components reflect and account for local contextual differences in Australian public
170 antenatal settings, with options to adapt them to other antenatal care settings, such as GP-led or
171 private obstetric care. Elements such as the content of the website and the timing of the text
172 messages are easy to update to reflect the latest statistics and recommendations.

173 We anticipated that midwives might raise concerns about the intervention increasing the length of
174 consultations. However, this issue did not arise, and a similar multicomponent intervention trialled

175 in the US with paediatricians found that it increased conversation efficiency without increasing
176 consultation time (7). Additionally, though previous research suggested that some midwives may be
177 reluctant to recommend vaccination (25), midwives in our study emphasised that they could and did
178 make vaccine recommendations.

179 Study limitations

180 This study had some limitations. The focus group sample size was small for a standalone qualitative
181 study, but it was the second round of an iterative process that built on substantial additional
182 published literature and our Round 1 interviews. While we were able to incorporate most of the
183 midwives' feedback, suggestions to translate parent materials into other languages or provide face-
184 to-face facilitated group training were not feasible due to budget constraints. It was also outside the
185 study scope to adapt the intervention for different models of antenatal care, although this is
186 planned. Though we did not involve parents directly in this study, our intervention is informed by
187 well-established data on the vaccination information needs and preferences of pregnant women and
188 parents (12, 18, 20, 21).

189 Conclusion

190 Suboptimal coverage of vaccines in pregnancy presents a major risk for maternal and infant health.
191 Furthermore, as new maternal vaccines are introduced (e.g. Group B Streptococcus and Respiratory
192 Syncytial Virus), maternal vaccination discussions will become more challenging and complex. P3-
193 MumBubVax is the first multi-component intervention in Australia to target the practice, provider
194 and parent levels to promote acceptance and uptake of maternal and childhood vaccines. The P3-
195 MumBubVax intervention package is being piloted to evaluate feasibility and acceptability. This will
196 inform a national cluster-randomised controlled trial to evaluate its efficacy and potential to adapt
197 to other antenatal care settings.

198 References

- 199 1. Mak DB, Regan AK, Vo DT, Effler PV. Antenatal influenza and pertussis vaccination in Western
200 Australia: a cross-sectional survey of vaccine uptake and influencing factors. *BMC Pregnancy Childbirth*.
201 2018;18(1):416.
- 202 2. Rowe SL, Perrett KP, Morey R, Stephens N, Cowie BC, Nolan TM, et al. Influenza and pertussis
203 vaccination of women during pregnancy in Victoria, 2015-2017. *Med J Aust*. 2019;210(10):454-62.
- 204 3. Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O'Leary ST, Omer SB. Enhancing uptake of influenza
205 maternal vaccine. *Expert Rev Vaccines*. 2019;18(2):191-204.

- 206 4. Frew PM, Lutz CS. Interventions to increase pediatric vaccine uptake: An overview of recent findings.
207 Hum Vaccin Immunother. 2017;13(11):2503-11.
- 208 5. Bednarczyk RA, Chamberlain A, Mathewson K, Salmon DA, Omer S. Practice-, Provider-, and Patient-
209 level interventions to improve preventive care: Development of the P3 Model. Preventive Medicine Reports.
210 2018;11:131–8.
- 211 6. Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortes M, et al. Improving influenza and
212 Tdap vaccination during pregnancy: A cluster-randomized trial of a multi-component antenatal vaccine
213 promotion package in late influenza season. Vaccine. 2015;33(30):3571-9.
- 214 7. Dempsey AF, Pyrznowski J, Lockhart S, Barnard J, Campagna EJ, Garrett K, et al. Effect of a Health
215 Care Professional Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A
216 Cluster Randomized Clinical Trial. JAMA Pediatr. 2018;172(5):e180016.
- 217 8. Gagneur A, Lemaître T, Gosselin V, Farrands A, Carrier N, Petit G, et al. A postpartum vaccination
218 promotion intervention using motivational interviewing techniques improves short-term vaccine coverage:
219 PromoVac study. BMC public health. 2018;18(1):811.
- 220 9. Krishnaswamy S, Wallace EM, Buttery J, Giles ML. Strategies to implement maternal vaccination: A
221 comparison between standing orders for midwife delivery, a hospital based maternal immunisation service
222 and primary care. Vaccine. 2018;36(13):1796-800.
- 223 10. Stockwell MS, Westhoff C, Kharbanda EO, Vargas CY, Camargo S, Vawdrey DK, et al. Influenza vaccine
224 text message reminders for urban, low-income pregnant women: a randomized controlled trial. Am J Public
225 Health. 2014;104 Suppl 1:e7-12.
- 226 11. Wiley K, Regan A, McIntyre P. Immunisation and pregnancy - who, what, when and why? Aust Prescr.
227 2017;40(4):122-4.
- 228 12. Danchin MH, Costa-Pinto J, Attwell K, Willaby H, Wiley K, Hoq M, et al. Vaccine decision-making
229 begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with
230 subsequent childhood vaccine uptake. Vaccine. 2017;36(44):6473-9.
- 231 13. Australian Institute of Health and Welfare. Australia's mothers and babies: 2016 in brief.
232 Australia2018.
- 233 14. Attwell K, Yusuf A, Frawley J. Is immunisation education in midwifery degrees adequate? Human
234 Vaccines & Immunotherapeutics. 2018;15(1):1-4.
- 235 15. Frawley JE, McKenzie K, Cummins A, Sinclair L, Wardle J, Hall H. Midwives' role in the provision of
236 maternal and childhood immunisation information. Women Birth. 2019;8 March 2019.

- 237 16. Kaufman J, Attwell K, Hauck Y, Omer S, Danchin M. Vaccine discussions in pregnancy: interviews with
 238 midwives to inform design of an intervention to promote uptake of maternal and childhood vaccines. *Human*
 239 *Vaccines & Immunotherapeutics*. 2019;May 24:1-10.
- 240 17. Rice RE, Atkin CK, editors. *Public Communication Campaigns*. 3rd ed. Thousand Oaks, CA: Sage
 241 Publications, Inc.; 2001.
- 242 18. Berry NJ, Danchin M, Trevena L, Witteman HO, Kinnersley P, Snelling T, et al. Sharing knowledge
 243 about immunisation (SKAI): An exploration of parents' communication needs to inform development of a
 244 clinical communication support intervention. *Vaccine*. 2018;36(44):6480-90.
- 245 19. Duffy C, Smith C. *Communications research on vaccination during pregnancy: Qualitative research*
 246 *report*. Crows Nest, NSW: Snapcracker Research + Strategy; 2018.
- 247 20. Kharbanda EO, Vargas CY, Castano PM, Lara M, Andres R, Stockwell MS. Exploring pregnant women's
 248 views on influenza vaccination and educational text messages. *Prev Med*. 2011;52(1):75-7.
- 249 21. Costa-Pinto J, Willaby H, Leask J, Hoq M, Schuster T, Ghazarian A, et al. Parental Immunisation Needs
 250 and Attitudes Survey in paediatric hospital clinics and community maternal and child health centres in
 251 Melbourne, Australia. *J Paediatr Child Health*. 2017;54(5):522-9.
- 252 22. King N. Doing Template Analysis. In: Symon G, Cassell C, editors. *Qualitative Organizational Research:*
 253 *Core Methods and Current Challenges*. London: SAGE Publications Ltd.; 2012.
- 254 23. Leask J, Kinnersley P, Jackson C, Cheater F, Bedford H, Rowles G. Communicating with parents about
 255 vaccination: a framework for health professionals. *BMC Pediatr*. 2012;12:154.
- 256 24. National Centre for Immunisation Research and Surveillance. Antenatal pertussis vaccination: timing
 257 updated. Available at: <http://www.ncirs.org.au/antenatal-pertussis-vaccination-timing-updated>. (Accessed 16
 258 May 2019). 2019 [Available from: <http://www.ncirs.org.au/antenatal-pertussis-vaccination-timing-updated>.
- 259 25. Pearce C, Leask J, Ritchie J. Tapping midwives' views about the neonatal hepatitis B vaccine: how
 260 welcome is a move towards a health promoting orientation? *Health Promot J Austr*. 2008;19(2):161-3.

261

262 **Table 1: Focus group participant details**

	VIC	WA
Number of focus group participants	n=5	n=13

Age range (n)	18-29 (3)	18-29 (2)
	30-39 (2)	30-39 (4)
	40-49 (0)	40-49 (3)
	50-59 (0)	50-59 (2)
	60+ (0)	60+ (2)
Years working as a midwife mean (SD)	3.6 (1.9)	14 (11.1)
In current role as a midwife, sees same mothers regularly (n)	Yes (0)	Yes (11)
	No (5)	No (2)
Midwifery qualifications (n)	Nursing Degree + Midwifery Qualification (3)	Nursing Degree + Midwifery Qualification (11)
	Direct Entry Midwifery Degree (2)	Direct Entry Midwifery Degree (1)
	Hospital based nursing and midwifery training (0)	Hospital based nursing and midwifery training (1)
Received immunisation training as part of midwifery qualification (n)	Maternal and childhood immunisation (4)	Maternal and childhood immunisation (4)
	Maternal immunisation only (1)	Maternal immunisation only (1)
	None at all (0)	None at all (7)*
Undertook Continuing Professional Development in immunisation (n)	Maternal and childhood immunisation (2)	Maternal and childhood immunisation (8)
	Maternal immunisation only (1)	Maternal immunisation only (2)
	None at all (2)	None at all (3)

263

*One participant was a midwifery student on placement so did not complete this question

Figure

Figure 1: P3-MumBubVax intervention package

